<p>Genor Biopharma Holdings Ltd. announced that its novel oral CDK4/6 inhibitor, Lerociclib (GB491), has been included in China’s 2025 National Reimbursement Drug List (NRDL), as published by the National Healthcare Security Administration. This marks the first time Lerociclib (GB491) has been added to the NRDL, with the new edition taking effect from January 1, 2026. The inclusion is expected to improve patient access and support commercialization efforts for the drug in China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251208-11948386), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

06998

<p>Genor Biopharma's Lerociclib has been added to China's 2025 National Reimbursement Drug List, effective January 1, 2026. This inclusion aims to enhance patient access and support the drug's commercialization in China.</p>

Genor Biopharma's Lerociclib Added to China National Reimbursement Drug List